Table 4.

Antipsychotic Risk for Clinically Important Weight Gain.

Category	Risk of Clinically Important Weight Gain, %a	Antipsychotic
Lower	<12	Aripiprazole, asenapine, and ziprasidone
Intermediate	10-24	Lurasidone, other FGAs, paliperidone, perphenazine, quetiapine, and risperidone
Higher	>24	Chlorpromazine, clozapine, and olanzapine

FGA, first-generation antipsychotic.

^aEstimated are rates of clinically important weight gain (equaling a net weight gain of 7% or greater from baseline weight) within ∼9 months of treatment.